CA-EXPERIAN
22.5.2024 12:01:30 CEST | Business Wire | Press release
As companies around the globe grapple with an accelerated pace of change and seek ways to optimize their businesses, Experian® is ushering in a new era of simplification, scalability and automation through the debut of new enhancements to its cloud-based Experian Ascend Technology Platform™. Now, Experian’s award-winning platform brings together software tools for analytics, credit decisioning and fraud into a single interface — simplifying the deployment of analytical models and enabling businesses to optimize their practices more frequently, achieving greater efficacy with lower investment of time and money.
Experian’s enhancements were unveiled to more than 500 business leaders during its annual Vision conference in Scottsdale, Ariz., and represent a significant evolution in streamlining business-to-business software solutions.
Why it matters:
- The world’s top technology companies have set the standard for seamless user experiences and integrations between software components through single sign-on, data portability, and sophisticated no-code or low-code functionality.
- Historically, this type of synchronized experience has been unattainable to many businesses, especially those in the financial services sector.
- Typically, organizations buy software solutions from many different vendors, leverage a variety of tools and applications across different cloud environments, and go through rigorous and time-consuming processes to stitch everything together.
- This fragmented approach stretches timelines unnecessarily, raises security concerns and creates operational challenges. It also increases costs and the likelihood of errors or downtime because such setups are only as strong as their weakest link, perpetually causing issues when any single component fails.
“IT services companies are increasingly delivering their software portfolios as pre-integrated platforms that deliver scale, efficiency, productivity,” said Raymond Pucci, IDC Research Director, Worldwide Lending Digital Strategies. “For lenders, enterprise architectures like Experian's Ascend Technology Platform can enable faster credit-decisioning velocity, higher loan quality, and stronger risk management, expanding customer relationships and increasing business growth.”
The updates to Experian’s platform represent a notable milestone — fueled by Experian’s significant investments in innovation over the last eight years as part of its modern cloud transformation.
“Our mission is to develop world-class software and support organizations around the world on their journeys toward more sophisticated fraud prevention, marketing and credit strategies,” said Alex Lintner, CEO, Experian Software Solutions. “The evolution of our platform reaffirms our commitment to drive innovation and empower businesses to thrive. Its capabilities are unmatched and represent a significant leap forward in lending technology, democratizing access to data in compliant ways while enabling lenders of all sizes to seamlessly validate their customers’ identities with confidence, help expand fair access to credit and offer awesome user and customer experiences.”
Experian’s global scalability
Experian’s platform is available now in regions including North America, Brazil and the United Kingdom. The enhanced platform is being leveraged by more than 1,500 clients globally, processing 14 million credit reports daily and billions of credit and fraud transactions per year. In North America alone, over 8,000 registered users from 80 clients access over 12 petabytes of data weekly for analytical purposes.
A simplified and scalable approach
The enhanced Experian Ascend Technology Platform now dramatically reduces time to install and offers streamlined access to many of Experian's award-winning integrated solutions and tools through a single sign-on and managed via a user-friendly dashboard.
The platform leverages generative AI and makes it easy for clients from organizations of varying sizes and experience levels to pivot between applications, automate processes, modernize operations and drive efficiency. In addition, existing clients using Experian solutions today can now easily add new capabilities through the platform to enhance business outcomes.
For example, Lendr, a specialized fintech offering contemporary financing solutions for small businesses, is harnessing the power of the platform to enhance competitiveness and informed decision-making.
“Utilizing Experian Ascend Technology Platform has significantly bolstered our agility and competitive edge, empowering us to execute more informed, data-driven credit decisions while substantially reducing our time to market,” remarked Daniel DeMeo, CEO of Lendr. “Experian’s platform helps deliver the scalability we need to be nimble, compete effectively and mitigate losses — ultimately helping us double our business over the past year.”
Additional key features and benefits of the platform include:
- Analytics and model development: Clients can easily access and harness Experian's proprietary credit and expanded data attributes with powerful analytical tools for insights and explainable model creation.
- Rapid model deployment: Build, test and deploy models from a single interface in days rather than months, streamlining processes and enhancing customer experiences.
- Automated decisioning and risk mitigation: Enables secure, automated decisions and risk mitigation across the customer lifecycle, ensuring efficient operations and improved outcomes.
- Fraud and identity verification: Experian’s platform stops fraudsters faster and streamlines consumer experiences via a suite of software services powered by advanced AI analytics and comprehensive data assets across digital identity, device intelligence, behavioral analytics and credit insights. It delivers unrivaled identity verification and fraud risk detection to enable businesses to grow revenue through seamless consumer experiences and reduce fraud loss exposure.
- Expertise through managed services: While the platform offers automation and low-code functionality, clients can also access Experian’s expertise and top talent through managed services, democratizing advanced analytics techniques for lenders regardless of their resources or analytics experience.
- Continuous monitoring and feedback: Receive continuous monitoring and feedback to adapt strategies in real time and stay ahead of evolving challenges.
- Unparalleled security: The platform is fortified with encryption, robust access controls and proactive threat detection — while maintaining high availability and Enterprise-grade performance.
For more information about Experian’s platform, please visit https://www.experian.com/business/products/ascend.
About Experian
Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realize their financial goals and help them to save time and money.
We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments.
We invest in talented people and new advanced technologies to unlock the power of data and innovate. As a FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 22,500 people across 32 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240522675866/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
